The results of this randomised controlled trial provide rationale for a shorter, 3-month course of #romosozumab compared with the standard 12-month regimen, thereby reducing cost and injection burden while potentially limiting cardiovascular risk www.thelancet.com/journals/lan...
#osteoporosis

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial In postmenopausal women at high risk of fracture, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip BMD. Given the expense,...

"The results of this randomised controlled trial provide rationale for a shorter, 3-month course of #romosozumab compared with the standard 12-month regimen, thereby reducing cost and injection burden while potentially limiting cardiovascular risk" www.thelancet.com/journals/lan...
#OpenAccess

3 months of romosozumab: a pragmatic clinical solution A longstanding goal in the treatment of osteoporosis has been rejuvenating the ageing skeleton to essentially reverse or cure osteoporosis. Although antiresorptive drugs such as bisphosphonates or den...

Sundeep Khosla comments on:
3 months of #romosozumab: a pragmatic clinical solution thelancet.com/journals/lan...
#postmenopausal #osteoporosis #BoneHealth #WomensHealth
#FREE to read with registration (also FREE)

#MedSky #EndoSky #RheumSky

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial In postmenopausal women at high risk of fracture, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip BMD. Given the expense,...

New—3 months vs 12 months of #romosozumab for #postmenopausal #osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial thelancet.com/journals/lan...
#BoneHealth #WomensHealth
#OpenAccess

#MedSky #EndoSky #RheumSky

Amgen/UCB: Romosozumab aprobado para su comercialización por la NMPA en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Romosozumab #Osteoporosis #Postmenopáusica #NMPA #Amgen #UCB #Biológicos #SaludÓsea #AprobaciónRegulatoria

Global data highlights effectiveness of romosozumab - PharmaTimes Studies show improved bone mineral density and healthcare cost reductions

#osteoporosis #UCB #romosozumab #clinicalstudies #bonemineraldensity #osteoporosistreatment #osteoporosistreatment #boneformation #boneresorption #WCOIOFESCEO2025 #systematicliteraturereview #realworldevidence #severeosteoporosis #osteoporosismanagement
pharmatimes.com/news/global-...

Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses Abstract. This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bis

Comparative cardiovascular safety of #romosozumab versus #bisphosphonates in Japanese patients with #osteoporosis: a new-user, active comparator design with instrumental variable analyses
academic.oup.com/jbmr/advance...

Verifying the effectiveness of romosozumab re-administration on bone mineral density Abstract. Upon completing romosozumab therapy for osteoporosis, sequential treatment with other agents is required. However, for patients at high fracture

The effectiveness of #romosozumab re-administration on #bone #mineral density
...though not reimbursed in Belgium, a second course appeared more effective than alternatives in patients who were still at high risk after a first course @asbmr.bsky.social
academic.oup.com/jbmr/advance...

The December issue is now online!

Read our latest articles!

🔗 onlinelibrary.wiley.com/toc/13652796...

#Glucocorticoids #romosozumab #denosumab #Alpha1antitrypsindeficiency #depression #stroke #PCI #amyloidosis #CKD #GLP1 #ECMO #CPR

#OnlineFirst w/ #PMT #JPharmTechnol this week: Primary care providers should prescribe #romosozumab for patients w/high fracture risk not responding to prior treatments, in a review by Yang & colleagues @Larkin U
#osteoporosis #womenshealth #pharmacists #pharmacy
journals.sagepub.com/doi/abs/10.1...